Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Microsoft has a new machine learning tool to improve weather forecasts

October 14, 2026

Doug Ford says Republicans might ‘pull the carpet’ under Trump if midterms are lost

October 14, 2026

Honey, Xbox shrunk its controller

October 14, 2026

Danielle Smith votes to stay in Canada, urges support for other 9 questions

October 14, 2026

Céline Dion gets her own Barbie inspired by iconic 1998 Oscars look

October 14, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Generic Pharmaceuticals Contract Manufacturing Market Analysis Report 2026: $93.56 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
Press Release

Generic Pharmaceuticals Contract Manufacturing Market Analysis Report 2026: $93.56 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

By News RoomApril 30, 20263 Mins Read
Generic Pharmaceuticals Contract Manufacturing Market Analysis Report 2026: .56 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
Share
Facebook Twitter LinkedIn Pinterest Email

Dublin, April 30, 2026 (GLOBE NEWSWIRE) — The “Generic Pharmaceuticals Contract Manufacturing Market Report 2026” has been added to ResearchAndMarkets.com’s offering.

The generic pharmaceuticals contract manufacturing market is experiencing robust growth. Projected to expand from $66.82 billion in 2025 to $71.65 billion in 2026, the market is set to continue ascending to an estimated $93.56 billion by 2030 at a CAGR of 6.9%. This growth is driven by increasing demand for generic drugs, the expansion of contract manufacturing organizations (CMOs), and a focus on advanced formulation technologies and biologics. The industry’s key trends include outsourcing for manufacturing, cost-effective production, and expansion into injectables and tablets, bolstered by improved regulatory compliance and licensing for generic products.

The rise of biosimilars is significantly directing the market’s trajectory. These affordable alternatives to costly biologic therapies enhance access to advanced treatments. Contract manufacturing supports the biosimilars sector with cost-efficient, large-scale production and regulatory expertise. According to Cardinal Health Inc., the U.S. witnessed an increase in FDA-approved biosimilars to 40 by 2023, highlighting the sector’s substantial growth potential.

Companies are establishing dedicated subsidiaries to meet the surging demand for contract manufacturing. For example, in 2025, Lupin launched Lupin Manufacturing Solutions (LMS) to specialize in contract development and manufacturing organization (CDMO) services, focusing on APIs. This strategic move positions them to provide high-quality contract manufacturing that emphasizes regulatory compliance and cost efficiency.

Additionally, Bora Pharmaceuticals acquired Upsher-Smith Laboratories for $210 million in April 2024, enhancing Bora’s capabilities across the pharmaceutical value chain. This acquisition broadens Bora’s reach from drug development to packaging and distribution.

Major players in the market include WuXi AppTec, Recipharm AB, Siegfried Holding AG, Curia Global Inc., and Piramal Pharma Solutions, among others. In 2025, North America led the market, with Asia-Pacific expected to be the fastest-growing region due to the shift in manufacturing norms and focus on local sourcing.

The market is adapting to tariff impacts on materials, encouraging local sourcing and domestic manufacturing investments to combat increased costs. This adaptation drives innovation in production processes, bolstering regional manufacturing capabilities.

Covering regions such as Asia-Pacific, North America, and Europe, the market report highlights growth opportunities, trends, and challenges. The generic pharmaceuticals contract manufacturing sector is poised for substantial expansion, driven by technological advancements and a shift toward biosimilars, underlining its critical role in global drug production.

Key Attributes:

Report Attribute Details
No. of Pages 250
Forecast Period 2026 – 2030
Estimated Market Value (USD) in 2026 $71.65 Billion
Forecasted Market Value (USD) by 2030 $93.56 Billion
Compound Annual Growth Rate 6.9%
Regions Covered Global


Report Scope:

  • By Drug Type:Branded Generics; Unbranded Generics
  • By Product Type:APIs; Formulations; Capsules; Tablets; Injectables
  • By Route Of Administration:Oral; Parenteral; Topical; Other Routes
  • By Application:Oncology; Immunology; Antidiabetic; Neurology; Anticoagulants; Cardiovascular; Respiratory; Pain; HIV Antivirals
  • By End-User Industry:Pharmaceutical Companies; CROs; Biotech Companies; Generic Drug Manufacturers

Companies Featured

  • WuXi AppTec Co. Ltd.
  • Recipharm AB
  • Siegfried Holding AG
  • Curia Global Inc.
  • Piramal Pharma Solutions
  • Laurus Labs Limited.
  • Cambrex Corp.
  • Alcami Corp. Inc
  • Neuland Laboratories Limited.

For more information about this report visit https://www.researchandmarkets.com/r/vuqg1z

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  • Generic Pharmaceuticals Contract Manufacturing Market

            
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

vineyard vines Returns as Official Style of the Head Of The Charles® Regatta

Bigger & Better Than Ever: Laxmi & Chef Kunal Kapur Return With ‘Diwali Delights’ Season 2

2026 Chery International User Summit to Kick Off: LUXEED Set for Global Brand Launch

Going Asset Management Wins Capital’s Excellence Fund Award, Harnessing Technology to Enhance the Long-Term Value of Assets

Alation Honors 2026 AI Radicals Award Winners at revAlation

Supported Employment: Helping Individuals Build Meaningful Careers

“The Carbon Pursuit of Happiness” Premieres October 10: A New Chapter for In-Depth Dialogue on Health and Humanity

Evolution Metals & Technologies Corp. Raises Fiscal 2026 Revenue Guidance 62% at Midpoint to 11 Million and Reaffirms 460 Million Fiscal 2027 Outlook

Ufunded Launches “Spotlight” Series, Documenting the Minds Shaping Modern Trading

Editors Picks

Doug Ford says Republicans might ‘pull the carpet’ under Trump if midterms are lost

October 14, 2026

Honey, Xbox shrunk its controller

October 14, 2026

Danielle Smith votes to stay in Canada, urges support for other 9 questions

October 14, 2026

Céline Dion gets her own Barbie inspired by iconic 1998 Oscars look

October 14, 2026

Latest News

OpenAI claims an ex-employee took its product plans and presented them to Apple

October 14, 2026

Major projects CEO faces B.C. First Nations’ frustrations over lack of consultations

October 14, 2026

The best feature of Apple’s HomeView might be its simplicity

October 14, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version